國家衛生研究院 NHRI:Item 3990099045/11275

NHRI > National Institute of Infectious Diseases and Vaccinology > Huey-Kang Sytwu > Periodical Articles > Item 3990099045/11275

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11275

Title:	SUMO-defective c-Maf preferentially transactivates Il21 to exacerbate autoimmune diabetes
Authors:	Hsu, CY;Yeh, LT;Fu, SH;Chien, MW;Liu, YW;Miaw, SC;Chang, DM;Sytwu, HK
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	SUMOylation is involved in the development of several inflammatory diseases, but the physiological significance of SUMO-modulated c-Maf in autoimmune diabetes is not completely understood. Here, we report that an age-dependent attenuation of c-Maf SUMOylation in CD4+ T cells is positively correlated with the IL-21-mediated diabetogenesis in NOD mice. Using 2 strains of T cell-specific transgenic NOD mice overexpressing wild-type c-Maf (Tg-WTc) or SUMOylation site-mutated c-Maf (Tg-KRc), we demonstrated that Tg-KRc mice developed diabetes more rapidly than Tg-WTc mice in a CD4+ T cell-autonomous manner. Moreover, SUMO-defective c-Maf preferentially transactivated Il21 to promote the development of CD4+ T cells with an extrafollicular helper T cell phenotype and expand the numbers of granzyme B-producing effector/memory CD8+ T cells. Furthermore, SUMO-defective c-Maf selectively inhibited recruitment of Daxx/HDAC2 to the Il21 promoter and enhanced histone acetylation mediated by CREB-binding protein (CBP) and p300. Using pharmacological interference with CBP/p300, we illustrated that CBP30 treatment ameliorated c-Maf-mediated/IL-21-based diabetogenesis. Taken together, our results show that the SUMOylation status of c-Maf has a stronger regulatory effect on IL-21 than the level of c-Maf expression, through an epigenetic mechanism. These findings provide new insights into how SUMOylation modulates the pathogenesis of autoimmune diabetes in a T cell-restricted manner and on the basis of a single transcription factor.
Date:	2018-08
Relation:	Journal of Clinical Investigation. 2018 Aug;128(9):3779-3793.
Link to:	http://dx.doi.org/10.1172/jci98786
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0021-9738&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000443283400020
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85052596996
Appears in Collections:	[Huey-Kang Sytwu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB30059018.pdf		3783Kb	Adobe PDF	339	View/Open

Loading...